Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 4, 2025International Journal of Molecular SciencesOpen Access

Proteome-Based Biomarkers for Alzheimer’s Disease: Old Acquisitions and Innovative Proposals

View Full Paper
Ask AI
Bookmark
Share

Authors

VMValeria MagnelliCPCorinna Anais PaganoMSMaurizio Sabbatini

Discussion

Loading...

Member takes

Overview

Review reveals cognitive impairment and mitochondrial function tracking in plasma and CSF, suggesting proteomic biomarkers may enhance diagnosis and treatment of Alzheimer's disease.

Key Points

  • Cognitive impairment and dementia are critical outcomes monitored through proteomic biomarkers.
  • The review emphasizes identifying biomarkers in plasma and cerebrospinal fluid for early Alzheimer's detection.
  • Assessment focuses on synaptic transmission and mitochondrial function indicators, showing potential progression monitoring.
  • Ongoing challenges highlight the need for sensitive and specific biomarkers for various Alzheimer's stages.

Cite This Study

Magnelli et al. (2025) studied this question.

synapsesocial.com/papers/6930e8c6ea1aef094cca352bhttps://doi.org/10.3390/ijms262311654
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease2025 · 11 citations
  2. 2Proximity extension assay-based proteomic studies in Alzheimer’s disease2024
  3. 3Blood-Based Biomarkers in Alzheimer's Disease: Advancing Non-Invasive Diagnostics and Prognostics2024 · 13 citations
  4. 4Post-Translational Modifications in Alzheimer's Disease and the Potential for New Biomarkers2014 · 26 citations
  5. 5The Role of Blood-Based Biomarkers in Transforming Alzheimer’s Disease Research and Clinical Management: A Review2025 · 18 citations